PSA Screening for Prostate Cancer Among Men With BRCA2 Mutations

Mutations in BRCA1 and BRCA2 genes are highly associated with increased risk of breast and ovarian cancer among women. In men, presence of between BRCA2 mutations has been shown to be associated with an increased risk of prostate cancer and overall poor prognosis. Early detection is key in successful treatment of prostate cancer, and prostate […]

Read More

Predicting Six-Month Mortality Among Patients With Cancer

When physicians have conversations with their patients regarding advanced care early during treatment, it results in patients receiving care that is in line with their goals and wishes. While guidelines recommend conversations with high-risk patients regarding advanced care, many patients with cancer die without ever having had this conversation. Because oncologists are only able to […]

Read More

Regular Aspirin Use Associated With Prolonged Survival for Biliary Tract Cancer

Biliary tract cancer (BTC) is a rare, difficult-to-treat gastrointestinal (GI) cancer that typically presents at late stages and has a poor prognosis. Thoughts are that Aspirin has an anticancer effect due to its anti-inflammatory and anticlotting activities. An analysis recently published in JAMA Oncology evaluated the impact of prolonged aspirin use in 2,934 patients with BTC […]

Read More

Olaparib Improves Outcomes in BRCA-Altered Castration-Resistant Prostate Cancer

Mutations in the DNA damage repair genes BRCA 1 and BRCA2 increase a tumor’s susceptibility to treatment with poly(ADP)ribose polymerase (PARP) inhibitors. This treatment approach is standard in breast and ovarian cancers, where these mutations commonly occur. Mutations in BRCA1/2 and the DNA damage repair gene ATM occur in as many as 30% of patients […]

Read More

CDK4/6 Inhibitors Demonstrate Consistent Survival Benefit in Breast Cancer

For patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, treatment with a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor in combination with endocrine therapy is a highly effective treatment option. Three CDK4/6 inhibitors are currently approved in the United States in this setting. At the ESMO Congress 2019, final results from the MONARCH 2 […]

Read More

Postsurgical Radiotherapy Not Necessary for Prostate Cancer

For men with early-stage prostate cancer, the standard of care for many years has been radical prostatectomy followed by adjuvant radiotherapy to prevent disease recurrence. However, the benefits of radiotherapy in this setting are not well documented and can be associated with numerous toxic effects. At the ESMO Congress 2019, results from a large clinical […]

Read More

Nivolumab/Ipilimumab Associated With High Rates of Long-Term Survival in Melanoma

In the past decade, the 5-year survival rate for patients with metastatic melanoma has increased dramatically, from less than 5% with chemotherapy to 20% with ipilimumab monotherapy. More recently, the introduction of PD-1 and PD-L1 inhibitors into the care of patients with metastatic melanoma has further improved survival outcomes, particularly when used in combination with […]

Read More

Two Years of Hormone Therapy Increases Mortality in Recurrent Prostate Cancer

Treatment with antiandrogen therapy is a standard of care for men with prostate cancer receiving salvage radiotherapy following postsurgical biochemical recurrence. This standard, based in part on results from the randomized phase III RTOG 9601 trial, found that the addition of 2 years of antiandrogen therapy to postoperative radiotherapy resulted in a significant improvement in […]

Read More

Survival Benefit for Induction Chemo in Nasopharyngeal Carcinoma

The majority of patients diagnosed with nasopharyngeal carcinoma are at an advanced stage and have a poor prognosis. Concurrent platinum-based chemotherapy and radiation is currently the standard of care for these patients with high risk, but this treatment is associated with a high rate of relapse. In phase II trials, induction chemotherapy with gemcitabine and […]

Read More

SCLC

Durvalumab Improves OS for Extensive Stage Small Cell Lung Cancer

Extensive stage small cell lung cancer (SCLC) has historically been associated with limited treatment options and a poor prognosis. In recent years, immunotherapy with PD-1 and PD-L1 targeting antibodies has emerged as an effective treatment option for these patients with progressive disease. Recently, the PD-L1 inhibitor atezolizumab was approved for use in the first-line setting […]

Read More